Current stock page

Stock Analysis

Halozyme Therapeutics, Inc. (HALO) Stock Analysis

Halozyme Therapeutics, Inc. (HALO) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

HALO Stock Analysis Summary

Halozyme Therapeutics, Inc. (HALO) currently has an AIQ Score of 78/100, indicating a bullish setup. Momentum is the strongest factor at 84/100. Risk is the weakest current factor at 63/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

HALO at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$100.27
AIQ Score78/100
Overall ViewBullish
Technical Analysis ConsensusStrong Sell
Market Cap$12.56B
P/E Ratio (TTM)23.87
Forward P/E—
EPS (latest quarter)—
Revenue (latest quarter)—
Dividend Yield (TTM)0.00%
Beta0.58
Volume2.28M
52-week range$61.23-$134.00
RSI 1426.68
50-Day SMA$114.56
200-Day SMA$85.43
Analyst Price Target—
Next Earnings—
As of Nov 13, 2026 · Market close

HALOHalozyme Therapeutics, Inc.

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$100.27−$0.40 (−0.40%)

Latest quote

  • Momentum
    84
  • Value
    76
  • Quality
    81
  • Risk resilience
    63
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

HALO Stock Analysis Summary

Halozyme Therapeutics, Inc. (HALO) currently has an AIQ Score of 78/100, indicating a bullish setup. Momentum is the strongest factor at 84/100. Risk resilience is the weakest current factor at 63/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, HALO has AIQ Score of 78/100 with Momentum base of 84/100 and fading Risk resilience at 63/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (84/100) leads while Risk resilience (63/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -0.40% stock move · HALO classified in Biotechnology.

Current Evidence

BullishHALO is in a bullish AIQ regime; Momentum is the strongest visible factor at 84/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is HALO Bullish or Bearish Right Now?

HALO currently has a bullish overall setup. Momentum is the strongest factor at 84/100, while Risk Resilience is weakest at 63/100. The current evidence suggests a constructive setup.

Bull Case
  • - Quality is supportive at 81/100.
  • - Momentum is constructive at 84/100.
Bear Case
  • - Technical consensus has more sell votes than buy votes (34 vs 10).

Current Consensus

HALO's Technical Analysis Consensus is currently Strong Sell, with 10 buy, 1 neutral, and 34 sell votes. HALO's 14-day RSI is 26.68, which places the stock in an oversold momentum range. HALO's beta is 0.58, indicating lower market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in HALO?

Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.

AIQ Score
78/100
Momentum
84/100
Quality
81/100
Risk
63/100

What Would Change the HALO Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

HALO Decision Framework

Public evidence layers, setup checks, and risk context for Halozyme Therapeutics, Inc..

Halozyme Therapeutics, Inc. (HALO) Stock Analysis

Halozyme Therapeutics, Inc. has an AIQ Score of 78/100 in a Bullish regime. Momentum is strongest at 84/100. Beta is 0.58, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextHALO is in a Bullish AIQ regime with score 78/100.
Signal ConflictThe primary conflict is that momentum leads at 84/100 while risk lags at 63/100.
Factor EvidenceMomentum 84/100 · Value 76/100 · Quality 81/100 · Risk 63/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 84/100.

TimingPass

Momentum is 84/100 and RSI (14) is 26.7.

Regime fitPass

HALO is in a Bullish regime at 78/100.

Risk controlWait

Risk factor is 63/100 with beta 0.58 and annual volatility 41.04%.

ConflictWait

Current conflict: momentum leads at 84/100 while risk lags at 63/100.

AIQ Score
78/100
Price
$100.27
Beta
0.58
RSI (14)
26.7

HALO Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

HALO Fundamentals

HALO valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
—
Net income
—
Free cash flow
—
View full HALO fundamental analysis

HALO Technical Analysis

HALO technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
26.68
Price vs SMA-50
-12.48%
View full HALO technical analysis

HALO Stock Catalysts

Track HALO earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
—
Analyst target
—
News items
0
View HALO earnings and stock catalysts

HALO Dividend Analysis

HALO dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View HALO dividend history and analysis

HALO Financial Data

HALO revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
—
EPS
—
Periods
—
View HALO financials

HALO Risk Analysis

HALO volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.58
Risk score
63/100
1Y volatility
41.04%
View HALO risk analysis

HALO Stock News

HALO stock news, market tone, recent headlines, and catalyst context.

News items
0
Updated
—
Sentiment
—
Read HALO stock news

HALO vs Biotechnology Peers

Current peer cohort: HALO · HRMY · IDYA · IMNM. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
HALO
Current stock
————0.9541.04%Current
HRMY
Harmony Biosciences Holdings, Inc.
————0.0740.59%HALO vs HRMY
IDYA
IDEAYA Biosciences, Inc.
————0.1444.94%HALO vs IDYA
IMNM
Immunome, Inc.
————0.4560.72%HALO vs IMNM
Pairwise Compare links: HRMY · IDYA · IMNMHALO vs HRMYHALO vs IDYAHALO vs IMNMCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a HALO stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for HALO: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

No quarterly financial rows in this snapshot.

Checked —

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
23.87
As of Nov 13, 2026
Revenue growth
—
Gross margin
82.27%
Current debt / equity
-58.84
Latest quarterly evidence

Quarterly financial history appears when reported fields are present.

Review fundamentals
Quarter revenue
—
Quarter net income
—
Quarter free cash flow
—

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bearish
RSI 14
26.68
MACD
-3.84

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
63/100
Beta
0.58
Annual volatility
41.04%
Max drawdown
-24.13%

HALO Stock FAQ

What is HALO stock price today?

Halozyme Therapeutics, Inc.'s current stock price is $100.27. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is HALO bullish or bearish right now?

HALO's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is HALO's market cap?

HALO's market cap is $12.56B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is HALO's current P/E ratio?

HALO's current P/E ratio is 23.87 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is HALO's RSI?

HALO's 14-day RSI is 26.68 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is HALO above its 50-day and 200-day moving averages?

HALO is -12.48% from its 50-day SMA and 17.38% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is HALO's next earnings date?

HALO's next earnings date is a key event to check before making a decision. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does HALO pay a dividend?

HALO's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.